Keros Depreciation vs Begin Period Cash Flow Analysis

KROS Stock  USD 19.42  0.59  3.13%   
Keros Therapeutics financial indicator trend analysis is infinitely more than just investigating Keros Therapeutics recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Keros Therapeutics is a good investment. Please check the relationship between Keros Therapeutics Depreciation and its Begin Period Cash Flow accounts. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Keros Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons.
For more information on how to buy Keros Stock please use our How to Invest in Keros Therapeutics guide.

Depreciation vs Begin Period Cash Flow

Depreciation vs Begin Period Cash Flow Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Keros Therapeutics Depreciation account and Begin Period Cash Flow. At this time, the significance of the direction appears to have almost identical trend.
The correlation between Keros Therapeutics' Depreciation and Begin Period Cash Flow is 0.91. Overlapping area represents the amount of variation of Depreciation that can explain the historical movement of Begin Period Cash Flow in the same time period over historical financial statements of Keros Therapeutics, assuming nothing else is changed. The correlation between historical values of Keros Therapeutics' Depreciation and Begin Period Cash Flow is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Depreciation of Keros Therapeutics are associated (or correlated) with its Begin Period Cash Flow. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Begin Period Cash Flow has no effect on the direction of Depreciation i.e., Keros Therapeutics' Depreciation and Begin Period Cash Flow go up and down completely randomly.

Correlation Coefficient

0.91
Relationship DirectionPositive 
Relationship StrengthVery Strong

Depreciation

Depreciation indicates how much of Keros Therapeutics value has been used up. For tax purposes Keros Therapeutics can deduct the cost of the tangible assets it purchases as business expenses. However, Keros Therapeutics must depreciate these assets in accordance with IRS rules about how and when the deduction may be taken, and how long it will last. The systematic allocation of the cost of a tangible asset over its useful life.

Begin Period Cash Flow

The amount of cash a company has at the beginning of a financial reporting period. It serves as the starting point for calculating the period's cash flow from operations, investing, and financing activities.
Most indicators from Keros Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Keros Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Keros Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons.
For more information on how to buy Keros Stock please use our How to Invest in Keros Therapeutics guide.Sales General And Administrative To Revenue is likely to gain to 218.00 in 2024, whereas Tax Provision is likely to drop 0.00 in 2024.
 2023 2024 (projected)
Depreciation And Amortization815K857.1K
Interest Income3.0M3.1M

Keros Therapeutics fundamental ratios Correlations

0.640.850.61.0-0.941.00.760.51-0.98-0.850.921.00.760.620.840.851.00.860.960.850.610.950.750.760.99
0.640.910.680.62-0.560.580.980.83-0.68-0.910.720.620.980.960.930.560.620.630.730.560.960.790.980.90.63
0.850.910.720.83-0.750.80.970.81-0.89-1.00.860.840.970.880.990.670.840.750.890.670.890.960.960.980.83
0.60.680.720.56-0.350.540.730.86-0.54-0.730.590.570.740.780.750.280.570.290.70.280.780.60.730.710.54
1.00.620.830.56-0.951.00.730.47-0.98-0.830.911.00.740.590.820.861.00.870.960.860.580.950.730.750.99
-0.94-0.56-0.75-0.35-0.95-0.95-0.65-0.270.930.76-0.93-0.95-0.65-0.46-0.72-0.96-0.95-0.96-0.9-0.96-0.45-0.89-0.64-0.66-0.94
1.00.580.80.541.0-0.950.70.43-0.97-0.790.91.00.70.550.790.861.00.860.950.860.540.930.690.70.98
0.760.980.970.730.73-0.650.70.86-0.79-0.960.780.741.00.960.980.60.740.670.820.60.970.881.00.940.73
0.510.830.810.860.47-0.270.430.86-0.55-0.80.470.490.870.940.850.160.490.240.60.160.940.650.870.810.45
-0.98-0.68-0.89-0.54-0.980.93-0.97-0.79-0.550.88-0.89-0.98-0.8-0.65-0.88-0.82-0.98-0.86-0.93-0.82-0.64-0.98-0.78-0.82-0.97
-0.85-0.91-1.0-0.73-0.830.76-0.79-0.96-0.80.88-0.88-0.83-0.96-0.87-0.98-0.7-0.83-0.77-0.9-0.7-0.88-0.95-0.96-0.98-0.83
0.920.720.860.590.91-0.930.90.780.47-0.89-0.880.90.790.620.830.920.90.930.960.920.620.910.770.820.9
1.00.620.840.571.0-0.951.00.740.49-0.98-0.830.90.750.60.830.851.00.860.950.850.590.950.730.750.99
0.760.980.970.740.74-0.650.71.00.87-0.8-0.960.790.750.960.990.60.750.670.830.60.960.891.00.940.73
0.620.960.880.780.59-0.460.550.960.94-0.65-0.870.620.60.960.930.390.60.470.70.391.00.760.970.860.59
0.840.930.990.750.82-0.720.790.980.85-0.88-0.980.830.830.990.930.640.830.710.890.640.920.940.980.950.81
0.850.560.670.280.86-0.960.860.60.16-0.82-0.70.920.850.60.390.640.850.990.831.00.390.790.590.610.87
1.00.620.840.571.0-0.951.00.740.49-0.98-0.830.91.00.750.60.830.850.860.950.850.590.950.730.750.99
0.860.630.750.290.87-0.960.860.670.24-0.86-0.770.930.860.670.470.710.990.860.840.990.470.850.670.70.88
0.960.730.890.70.96-0.90.950.820.6-0.93-0.90.960.950.830.70.890.830.950.840.830.690.950.810.810.92
0.850.560.670.280.86-0.960.860.60.16-0.82-0.70.920.850.60.390.641.00.850.990.830.390.790.590.610.87
0.610.960.890.780.58-0.450.540.970.94-0.64-0.880.620.590.961.00.920.390.590.470.690.390.750.970.870.58
0.950.790.960.60.95-0.890.930.880.65-0.98-0.950.910.950.890.760.940.790.950.850.950.790.750.870.890.93
0.750.980.960.730.73-0.640.691.00.87-0.78-0.960.770.731.00.970.980.590.730.670.810.590.970.870.930.73
0.760.90.980.710.75-0.660.70.940.81-0.82-0.980.820.750.940.860.950.610.750.70.810.610.870.890.930.75
0.990.630.830.540.99-0.940.980.730.45-0.97-0.830.90.990.730.590.810.870.990.880.920.870.580.930.730.75
Click cells to compare fundamentals

Keros Therapeutics Account Relationship Matchups

Keros Therapeutics fundamental ratios Accounts

201920202021202220232024 (projected)
Total Assets11.0M269.4M255.3M306.8M370.0M227.3M
Short Long Term Debt Total5.3M899K1.1M13.3M14.4M15.2M
Other Current Liab107K4.0M6.4M12.2M17.9M18.8M
Total Current Liabilities4.5M7.2M11.8M16.5M24.4M13.9M
Total Stockholder Equity5.5M261.7M243.2M277.4M332.2M207.7M
Net Tangible Assets(19.4M)261.7M243.2M277.4M319.0M166.3M
Property Plant And Equipment Net1.9M1.6M2.4M17.6M19.5M20.4M
Current Deferred Revenue1.9M4.4M7.1M17.3M19.8M20.8M
Net Debt(5.7M)(265.0M)(228.9M)(265.8M)(316.7M)(300.9M)
Retained Earnings(19.7M)(65.0M)(123.8M)(228.4M)(381.4M)(362.4M)
Accounts Payable2.1M2.1M3.6M3.3M5.5M3.1M
Cash7.0M265.9M230.0M279.0M331.1M208.3M
Non Current Assets Total2.0M1.7M3.8M21.0M22.7M23.9M
Other Assets115K993K1.4M3.4M4.0M4.2M
Cash And Short Term Investments7.0M265.9M230.0M279.0M331.1M208.3M
Liabilities And Stockholders Equity11.0M269.4M255.3M306.8M370.0M227.3M
Non Current Liabilities Total1.0M538K231K12.8M13.4M14.1M
Capital Surpluse203K326.7M366.9M505.9M581.7M610.8M
Capital Lease Obligations1.3M899K1.1M13.3M14.4M15.2M
Other Current Assets226K1.6M3.2M5.9M15.1M15.8M
Other Stockholder Equity25.1M596.2M366.9M505.9M713.6M404.8M
Total Liab5.5M7.7M12.1M29.4M37.8M19.6M
Net Invested Capital5.5M261.7M243.2M277.4M332.2M204.0M
Property Plant And Equipment Gross1.9M1.6M2.4M17.6M21.2M22.2M
Total Current Assets8.9M267.7M251.4M285.8M347.3M217.6M
Non Current Liabilities Other119K62K231K12.8M14.7M15.5M
Net Working Capital4.4M260.5M239.6M269.2M322.9M203.6M
Short Term Debt376K846K1.7M910K1.0M921.6K
Property Plant Equipment1.9M1.6M1.3M2.0M2.3M1.8M

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for Keros Stock Analysis

When running Keros Therapeutics' price analysis, check to measure Keros Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Keros Therapeutics is operating at the current time. Most of Keros Therapeutics' value examination focuses on studying past and present price action to predict the probability of Keros Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Keros Therapeutics' price. Additionally, you may evaluate how the addition of Keros Therapeutics to your portfolios can decrease your overall portfolio volatility.